title: Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing?
abstract: Acrodermatitis continua of Hallopeau (ACH) is a rare disease. Little is known about its etiology or relative effectiveness of the various therapeutic approaches. However, in the literature a pattern seems to be developing on successfully treated patients using biologic therapies. Here, we further emphasize the potential breakthrough presented by the novel immune based therapies. This report consists of a case of etanercept responsive ACH along with a brief review of the literature.
authors.affiliation: Department of Dermatology, Loyola Medical Center, Maywood, IL 60153, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Bonish
authors.forename: Rashid M
authors.initials: RM
authors.lastname: Rashid
authors.forename: James
authors.initials: J
authors.lastname: Swan
mesh_terms: D000169:Acrodermatitis / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D000279:Administration, Cutaneous; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003899:Desoximetasone / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D003899:Desoximetasone; D000068800:Etanercept